IFN-beta-1a vs Thymogen
Head-to-head comparison of IFN-beta-1a (Recombinant human interferon beta-1a) and Thymogen (L-Glutamyl-L-Tryptophan) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | IFN-beta-1a | Thymogen |
|---|---|---|
| Category | Immune Support | Immune Support |
| Full Name | Recombinant human interferon beta-1a | L-Glutamyl-L-Tryptophan |
| Molecular Weight | ~22,500 Da | 345.34 Da |
| Half-Life | 10-19 hours | 1-2 h |
| Amino Acids | 166 | 2 |
| Typical Dose | 30-44 mcg per dose | 100-300 mcg |
| Route | Intramuscular/Subcutaneous | Intranasal |
| Purity | ≥98% | ≥98% |
| Studies Count | 1200 | 60 |
| Research Status | Clinical | Clinical |
IFN-beta-1a Benefits
- ✓antiviral gene induction
- ✓innate immune modulation
- ✓reduced viral replication
- ✓well-characterized safety profile
Thymogen Benefits
- ✓cellular-immune-support
- ✓t-cell-signaling
- ✓recovery-adjunct
- ✓infection-resilience
IFN-beta-1a Dosing
30 mcg intramuscular weekly or 44 mcg subcutaneous three times weekly|Titrate by indication and tolerability|Monitor liver enzymes, blood counts, and injection reactions
Thymogen Dosing
100-300 mcg/day|intranasal or IM|5-10 day cycles
IFN-beta-1a Side Effects
- ⚠flu-like symptoms
- ⚠injection-site reactions
- ⚠liver enzyme elevation
Thymogen Side Effects
- ⚠nasal irritation
- ⚠headache
- ⚠hypersensitivity
Research Overview
IFN-beta-1a
Widely studied recombinant interferon beta preparation with a strong evidence base in immune modulation and antiviral biology. Its clinical use demonstrates predictable pharmacology and class-typical interferon effects.
Thymogen
Thymogen has been studied as a short thymic peptide-like dipeptide with immunoregulatory activity. The literature focuses on lymphocyte function, cytokine modulation, and use in recurrent respiratory infections or immune suppression states.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.